Clinical trial · Interventional
Multihance at 3 Tesla (3T) in Brain Tumors
A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T
NCT00395863CI-TRIAL-00048148completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Compare the efficacy of MultiHance and Magnevist
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Arm 2 - Magnevist | Drug | — | UNRESOLVED |
| Multihance | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- MultiHance
- description
- 0.5 M MultiHance at a single injection
- interventionNames
- Drug: Multihance
- type
- ACTIVE_COMPARATOR
- label
- Magnevist
- description
- 0.5 M Magnevist at a single injection
- interventionNames
- Drug: Arm 2 - Magnevist
Primary outcomes (1)
- measure
- Global Diagnostic Preference Between the Two Exams
- timeFrame
- Postdose Images for MultiHance Exam and for Magnevist Exam Compared
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Was 18 years or older * Provided written informed consent * Scheduled for MRI * Confirmed or highly suspected to have brain tumor(s) and willing to undergo two MRI exams within 14 days Exclusion Criteria: * Pregnant or lactating females * Allergy to one or more of the ingredients in the products or hypersensitivity to any metals * Congestive heart failure, class IV * Previous stroke in the past year * Received another contrast agent within 24 hours pre and post each exam * Investigational product * Contraindications to MRI * Severe claustrophobia * Surgery with 3 weeks prior * Steroid therapy or radiosurgery between two exams
References
Publications (1)
- RESULTRumboldt Z, Rowley HA, Steinberg F, Maldjian JA, Ruscalleda J, Gustafsson L, Bastianello S. Multicenter, double-blind, randomized, intra-individual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine in MRI of brain tumors at 3 tesla. J Magn Reson Imaging. 2009 Apr;29(4):760-7. doi: 10.1002/jmri.21695. PMID 19306364